» Articles » PMID: 8543387

Impaired Tumor Growth in Colony-stimulating Factor 1 (CSF-1)-deficient, Macrophage-deficient Op/op Mouse: Evidence for a Role of CSF-1-dependent Macrophages in Formation of Tumor Stroma

Overview
Journal Int J Cancer
Specialty Oncology
Date 1996 Jan 3
PMID 8543387
Citations 45
Authors
Affiliations
Soon will be listed here.
Abstract

Macrophages have been suggested to play a major role in the immune response to cancer. They have also been suggested to stimulate the formation of tumor stroma and to promote tumor vascularization. The availability of the op/op mouse, which has no endogenous colony-stimulating factor 1 (CSF-1) and which possesses a profound macrophage deficiency, provides a new model to verify these notions. Subcutaneous growth of transplantable Lewis lung cancer (LLC) is markedly impaired in the op/op mice compared with normal littermates. Treatment of tumor-bearing op/op mice with human recombinant CSF-1 corrects this impairment. Histological analysis of tumors grown in op/op and normal mice revealed marked differences. Tumors grown in op/op mice display a decreased mitotic index and pronounced necrosis, particularly hemorrhagic. Moreover, particularly in the op/op tumors, peculiar sinusoid-like abortive vessels (not filled with blood) have been observed. These tumors, in contrast to tumors grown in normal mice, are almost deprived of regular arteries and veins. In contrast to tumors grown in normal mice, they exhibit almost no Sirius red-stained collagenous fibers and Gomori silver-stained reticular fibers. Our data suggest that the CSF-1-dependent macrophage subpopulation missing in op/op mice plays a primary role in supporting tumor stroma formation and tumor vascularization in murine LLC tumors.

Citing Articles

MAFB shapes human monocyte-derived macrophage response to SARS-CoV-2 and controls severe COVID-19 biomarker expression.

Simon-Fuentes M, Rios I, Herrero C, Lasala F, Labiod N, Luczkowiak J JCI Insight. 2023; 8(24).

PMID: 37917179 PMC: 10807725. DOI: 10.1172/jci.insight.172862.


Breaking the 'don't eat me' signal: in silico design of CD47-directed peptides for cancer immunotherapy.

Laddha K, Sobhia M Mol Divers. 2023; 28(5):3067-3083.

PMID: 37759140 DOI: 10.1007/s11030-023-10732-5.


A phase I/II study of LY3022855 with BRAF/MEK inhibition in patients with Melanoma.

Buchbinder E, Giobbie-Hurder A, Haq R, Ott P Invest New Drugs. 2023; 41(4):551-555.

PMID: 37247116 DOI: 10.1007/s10637-023-01374-3.


A phase I/II study of MCS110 with BRAF/MEK inhibition in patients with melanoma after progression on BRAF/MEK inhibition.

Buchbinder E, Giobbie-Hurder A, Ott P Invest New Drugs. 2023; 41(3):365-370.

PMID: 37097370 DOI: 10.1007/s10637-023-01364-5.


Inhibition of LXR controls the polarization of human inflammatory macrophages through upregulation of MAFB.

de la Aleja A, Herrero C, Torres-Torresano M, Schiaffino M, Del Castillo A, Alonso B Cell Mol Life Sci. 2023; 80(4):96.

PMID: 36930354 PMC: 10020776. DOI: 10.1007/s00018-023-04745-4.